Background {#Sec1}
==========

Gout affects 2.5% of adults in the UK, with prevalence and incidence continuing to rise \[[@CR1], [@CR2]\]. The primary risk factor for gout is an elevated serum urate level (hyperuricaemia), leading to monosodium urate crystal deposition in and around joints, acute attacks of crystal synovitis and progressive joint damage \[[@CR3]\]. Long-term treatment of gout involves using urate-lowering therapies (ULT), typically allopurinol \[[@CR4]\] to inhibit xanthine oxidase, resulting in improved long-term outcomes. Despite this, treatment use remains suboptimal \[[@CR5]\] and, therefore, identifying populations at risk of developing gout, especially those in primary care where the majority of patients with gout are managed, may provide opportunities for primary prevention.

Body mass index (BMI) and hypertension have been identified as risk factors for incident gout in a number of large epidemiological studies \[[@CR6]\], yet the magnitude of risk varies between studies. Obesity promotes insulin resistance which in turn reduces renal urate excretion resulting in hyperuricaemia \[[@CR7]\]. Hypertension predisposes to gout by reducing renal urate excretion due to glomerular arteriolar damage and glomerulosclerosis. Diuretics are perhaps the most well-known medications to be associated with gout; they raise serum uric acid levels by increasing uric acid reabsorption and decreasing uric acid secretion in the kidneys. However, it has also been proposed that diuretic use alone does not increase the risk of gout and that the observed associated risk is due to the presence of co-morbidities which they are used to treat; commonly hypertension, heart failure and renal failure \[[@CR8]\]. Studying obesity, hypertension and diuretic use and their association with incident gout to elucidate the true nature and magnitude is important because all three are common and can be modified. We performed a systematic review of cohort studies with the aim of deriving pooled estimates of the risk of incident gout associated with obesity, hypertension and diuretic use.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

We searched MEDLINE, Embase, CINAHL and the Cochrane Library from their inception to March 2017. A combination of free-text and medical subject heading (MeSH) terms, or database-specific equivalents, were used (Appendix [1](#Sec18){ref-type="sec"}). Reference lists of included articles were searched for additional eligible articles.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

The inclusion criteria were developed using the PICOS framework \[[@CR9]\]. The population of interest was adults aged 18 years or older. Studies which included participants under the age of 18 years at cohort entry, but in whom outcome was assessed in adulthood, were deemed to meet this inclusion criterion. Articles were required to have examined at least one of: obesity (BMI ≥ 30 kg/m^2^), hypertension (self-reported, physician-diagnosed or study-defined mmHg value) or diuretic use (self-reported or reported in records) and their association with incident gout, defined as the first recorded episode (i.e. a subsequent new diagnosis of gout). Articles which studied the incidence of gout in specific hyperuricaemic populations were excluded. Included articles had to be cohort studies, prospective or retrospective and undertaken in primary care or the general population.

No restrictions were imposed on language or the time periods for publication, with medical literature databases searched from inception. Where full articles could not be obtained, these were requested from the corresponding author.

Screening process {#Sec5}
-----------------

After duplicates had been removed from the initial search, the titles and abstracts of all of the remaining articles were screened by two authors (PLE and CH). Two authors (PLE/CH and JAP) then independently reviewed the full text of the remaining articles to decide on inclusion. Any articles where there was disagreement about inclusion were subsequently arbitrated over by a third author (ER).

Data extraction and quality assessment {#Sec6}
--------------------------------------

Data were extracted from the full set of eligible articles by a single author (PLE/CH) and also extracted independently from a subset (50%) of the eligible articles by a second author (JAP). If risk estimates were not reported in the original articles, these were requested from the corresponding author. Extracted variables included author, year and title of publication, country in which the study took place, the number of years of follow-up, baseline demographics of participants which included age, gender and ethnicity, the number of cases of incident gout, the study setting (primary care or general population), exposure of interest and method of definition used, the method of gout diagnosis and the risk estimate of incident gout associated with that particular exposure, and both unadjusted and adjusted values were extracted if available. The methodological quality of all eligible articles was assessed independently by two authors (PLE/CH and JAP) using the cohort study template of the Newcastle--Ottawa Scale (NOS). Funnel plots were produced from the adjusted data points for each meta-analysis to examine the extent of any publication bias.

Statistical analysis {#Sec7}
--------------------

Narrative synthesis was used to summarise the characteristics of studies included in the systematic review. Estimates were pooled for an individual risk factor if there were a minimum of three values which met the criteria; the exposure was measured in a similar manner and used the same risk estimate (e.g. odds ratio (OR), relative risk (RR), hazards ratio (HR)). Firstly, unadjusted or minimal adjusted risk estimates were pooled for each individual risk factor, and then the maximal multivariate-adjusted risk estimates.

Pooled risk estimates were calculated using random-effects meta-analysis. A random-effects model is considered more appropriate for meta-analyses with the potential for substantial heterogeneity. Quantifying the inconsistency across studies was assessed using Cochran *Q* and *I*^2^ statistics. The DerSimonian and Laird random-effects models were then used to calculate the pooled risk together with associated 95% confidence intervals (CI). The meta-analysis was performed using STATA 13.

Results {#Sec8}
=======

Search results {#Sec9}
--------------

The search yielded a total of 9923 articles. Of these 3606 were duplicates and hence removed, leaving 6317 individual publications to be screened by title and abstract. Forty-nine articles could not be excluded by title and abstract and had their full text reviewed. Thirty-five articles were excluded (Appendix [2](#Sec19){ref-type="sec"}), 14 articles met the inclusion criteria \[[@CR10]--[@CR23]\], no additional articles were identified in their reference lists and a final 11 articles contained data suitable for pooling in the meta-analysis \[[@CR11], [@CR13]--[@CR18], [@CR22]--[@CR25]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Number of articles at each stage of the search and screening process

Characteristics of included articles {#Sec10}
------------------------------------

Thirteen of the 14 articles included in the systematic review used general populations, with one from primary care \[[@CR13]\] (Table [1](#Tab1){ref-type="table"}). The majority were from the USA, with the remaining four articles from the UK, Singapore \[[@CR22]\], Taiwan \[[@CR18]\] and Tokelau (South Pacific island) \[[@CR10]\]. Sample sizes for the included articles ranged from 923 to 60,181, with the number of incident cases of gout ranging from 43 to 1341. Two studies included only male participants---one using a cohort of male health professionals \[[@CR14]\] and the other a sample of male medical students \[[@CR12]\]---and one study included an all-female sample from the Atherosclerosis Risk in Communities (ARIC) study \[[@CR17]\]. The remaining 11 studies included both men and women, although the sample in one study was predominantly male (91%) \[[@CR11]\]. There was a majority of white participants (ranging from 62 to 100%) in the nine articles which reported the ethnic composition of their samples, with the exception of Prior et al. \[10\] which examined 100% Tokelauan. Two studies included participants who were aged under 18 years at study entry \[[@CR10], [@CR16]\], two studies included those in their mid-twenties (university students) \[[@CR11], [@CR12]\], seven studies included participants in middle-older age \[[@CR14], [@CR15], [@CR17], [@CR18], [@CR20], [@CR22], [@CR25]\], one study included participants in older age \[[@CR23]\] and two studies included wide age ranges (18--89 years) \[[@CR13], [@CR21]\]. The length of follow-up of participants ranged from 8 to 52 years.Table 1Characteristics of the included articles (*n* = 14)ArticleCountryStudy setting (study name)Age (years)GenderEthnicityYears of follow-upAscertainment of exposureAscertainment of gout diagnosisPrior et al. 1987 \[[@CR10]\]New Zealand and TokelauPopulation based≥ 15 at baseline, ≥ 18 at first\
follow-upMen and women included, but numbers not specified100% TokelauanUp to 14Hypertension: measurement of systolic and diastolic blood pressureHistory of ≥ 2 episodes of podagra with redness and swelling of first metatarsophalangeal jointRoubenoff et al. (1991) \[[@CR11]\]^a^USAPopulation based\
(medical students)\
(John Hopkins precursor study)Median 22Men: 1216 (91%); women: 121 (9%)White: 1301 (97%); non-white: 36 (3%)40Hypertension: self-reported SBP \> 160 mmHg or DBP \> 95 mmHg on two questionnaires or self-reported anti-hypertensive medication useSelf-report followed by medical chart reviewHochberg et al. (1995) \[[@CR12]\]^a^USAPopulation based (medical students)\
(John Hopkins precursor study)White: mean 26.1, SD 1.8; black: mean 29.0, SD 3.8Men: 923 (100%)White: 571 (62%); black: 352 (38%)26--34; mean 29Hypertension: self-reported SBP \> 160 mmHg or DBP \> 95 mmHg on two questionnaires or self-reported anti-hypertensive medication useSelf-report plus one of: history of MSU crystals or documented tophus or use of colchicine, probenecid or allopurinolGrodzicki et al. (1997) \[[@CR13]\]^a^UKPrimary care\
(general practice hypertension study)18--65Men: 1060 (50%); women: 1068 (50%)Not reportedAverage 8Hypertension: not reported\
Diuretic use: not reportedDiagnosed by GPChoi et al. (2005) \[[@CR14]\]^a^USAPopulation based (male healthcare professionals)\
(health professionals follow-up study)40--75,\
mean 54Men: 47,150 (100%)91% white12Obesity: self-reportedHypertension: self-reported physician-diagnosed hypertension\
Diuretic use: self-reportedSelf-report followed by ACR criteria (≥ 6/11 for diagnosis of gout)Bhole et al. (2010) \[[@CR15]\]^a^USAPopulation based\
(Framington heart study)Men: mean 46, SD 9; women: mean 47, SD 9Men: 1951 (44%); women: 2476 (56%)Not reported52; median 28Obesity: measured height and weight, BMI calculatedHypertension: average of two readings SBP ≥ 140 mmHg or DBP ≥ 90 mmHgDiuretic use: self-reportedClinical diagnosis at any follow-up study examinationMcAdams DeMarco et al. (2011) \[[@CR16]\]^a^USAPopulation based\
(CLUE II study)13--87 at baseline, ≥ 24 at first follow-upMen: 6100 (39%); women: 9433 (61%)White: 15,533 (100%)18Obesity: self-reportedSelf-reportMaynard et al. (2012) \[[@CR17]\]^a^USAPopulation based\
(ARIC)45--64Women: 6263 (100%)White: 4676 (75%); black: 1587 (25%)9Obesity: self-reportedSelf-reportChen et al.\
(2012) \[[@CR18]\]^a^TaiwanPopulation based\
(health insurance database)Men: mean 46, SD 9; women: mean 47, SD 9Men: 60,181 (45%); women: 72,375 (55%)--Median 7.31Hypertension: record linkageRecord linkage: diagnostic code of gout from ICD-9 + 2× prescriptions of colchicine + prescription of urate-lowering drugsMcAdams-DeMarco et al. (2012) \[[@CR25]\]^a^USAPopulation based\
(ARIC)45--64; mean 54, SD 5.7Men: 4709 (43%); women: 6163 (57%)White: 8538 (79%); black: 2334 (21%)9Hypertension: self-report of anti-hypertension medications or measured high blood pressureSelf-reportMcAdams DeMarco et al. (2012) \[[@CR20]\]USAPopulation based\
(ARIC)45--64; mean 54, SD 5.7Men: 2445 (42%); women: 3344 (58%)White: 3998 (69%); black: 1791 (31%)9Diuretic use: self-reportSelf-reportWilson et al. (2014) \[[@CR21]\]USAPopulation based\
(health insurance database)18--89Men: 1449 (48%); women: 1584 (52%)--Up to 12Diuretics: record linkage, chlorthalidone vs hydrochlorothiazideRecord linkage: ICD-9 for gout or allopurinol, febuxostat, colchicine, probenecidPan et al. (2015) \[[@CR22]\]^a^SingaporePopulation based\
(Singapore Chinese health study)Hyp. 61.3 (median);\
no Hyp. 59.3 (median)Hyp. men:\
4403 (40.7%);\
no Hyp. men: 7982 (40.4)--12Hypertension: self-report at recruitment interviewSelf-report and clinical verificationBurke et al. (2016) \[[@CR23]\]^a^USAPopulation based\
(ARIC)≥ 65No gout (*n* = 6535): men 43.4%;\
gout (*n* = 230): men 52.2%White: 100%25Hypertension: SBP ≥ 140 mmHg or DBP ≥ 90 mmHg, or use of a medication to treat hypertension\
Diuretic use: self-report of medication useSelf-report*ARIC* Atherosclerosis Risk In Communities, *ACR* American College of Rheumatology, *BMI* body mass index, CLUE (Give us a Clue to Cancer) II study, *DBP* diastolic blood pressure, *GP* general practitioner, *Hyp.* hypertension, *ICD-9* International Classification of Diseases, ninth revision, *MSU* monosodium urate, *SBP* systolic blood pressure, *SD* standard deviation^a^Included in meta-analysis (*n* = 7)

From the 14 articles included in this review, 11 were used within the meta-analysis. Seven articles were pooled as each had recorded a risk estimate for at least one of the risk factors of interest using RR (95% CI) and four articles were pooled based on their use of HRs (95% CI). The risk estimates from the remaining three articles were not sufficient to pool risk estimates (Table [2](#Tab2){ref-type="table"}).Table 2Risk estimates reported by included articles (*n* = 14)Risk factorAuthor and yearSample\
sizeCases of\
incident goutOutcome\
measureExposureRisk estimateMinimal adjustment modelMaximal adjustment modelObesityChoi et al. (2005) \[[@CR14]\]^a^47,150730RR (95% CI)BMI ≥ 30 kg/m^2^ at age 212.14 (1.37--3.32)^b^1.66 (1.06--2.60)^1^Bhole et al. (2010) \[[@CR15]\]^a^1951200RR (95% CI)BMI ≥ 30 kg/m^2^ in men3.50 (2.30--5.32)^b^2.90 (1.89--4.44)^2^2476104BMI ≥ 30 kg/m^2^ in women3.52 (2.16--5.72)^b^2.74 (1.65--4.58)^2^McAdams-DeMarco et al. (2011) \[[@CR16]\]^a^15,533517RR (95% CI)BMI ≥ 30 kg/m^2^ at age 212.06 (1.38--3.07)^c^1.82 (1.21--2.73)^3^Maynard et al. (2012) \[[@CR17]\]^a^6263106RR (95% CI)BMI ≥ 30 kg/m^2^ at age 254.30 (2.14--8.64)^b^2.84 (1.33--6.09)^4^HypertensionPrior et al. 1987 \[[@CR10]\]170546OR (95% CI)Systolic blood pressure0.03 (0.02--0.05)--Diastolic blood pressure0.05 (0.03--0.07)--Roubenoff et al. (1991) \[[@CR11]\]^a^127160RR (95% CI)Hypertension2.70 (1.45--5.13)--Hochberg et al. (1995) \[[@CR12]\]^a^92360RR (95% CI)Hypertension (incident)3.78 (2.18--6.58)3.20 (1.80--5.68)^5^Grodzicki et al. (1997) \[[@CR13]\]^a^212845RR (95% CI)Hypertension3.93 (1.60--9.70)--Choi et al. (2005) \[[@CR14]\]^a^47,150730RR (95% CI)Hypertension3.07 (2.64--3.56)^b^2.31 (1.96--2.72)^6^Bhole et al. (2010) \[[@CR15]\]^a^1951200RR (95% CI)Hypertension---men2.39 (1.73--3.29)^b^1.59 (1.12--2.24)^7^2476104Hypertension---women2.91 (1.74--4.88)^b^1.82 (1.06--3.14)^7^Chen et al. (2012) \[[@CR18]\]^a^60,1811341HR (95% CI)Hypertension---men1.74 (1.54--1.95)^b^1.32 (1.17--1.48)^8^72,375265Hypertension---women2.11 (1.59--2.79)^b^1.34 (1.02--1.77)^8^McAdams-DeMarco et al. (2012) \[[@CR25]\]^a^10,872274HR (95% CI)Hypertension (time-varying)2.87 (2.24--3.78)2.00 (1.54--2.61)^9^Pan et al. (2015) \[[@CR22]\]^a^31,137163\
201HR (95% CI)Hypertension---men\
Hypertension---women-\
-1.67 (1.33--2.09)^10^\
2.08 (1.66--2.60)^10^Burke et al. (2016) \[[@CR23]\]^a^2956\
3809120\
110HR (95% CI)Hypertension---men\
Hypertension---women1.33 (0.84--2.09)\
1.64 (1.02--2.64)-\
-Diuretic useGrodzicki et al. (1997) \[[@CR13]\]^a^212845RR (95% CI)Diuretic use (and raised diastolic blood pressure)6.25 (2.40--16.70)--Choi et al. (2005) \[[@CR14]\]^a^47,150730RR (95% CI)Diuretic use3.37 (2.75--4.12)^b^1.77 (1.42--2.20)^11^Bhole et al. (2010) \[[@CR15]\]^a^4427304RR (95% CI)Diuretic use in men4.31 (3.06--6.08)^b^3.41 (2.38--4.89)^12^Diuretic use in women3.23 (2.13--4.91)2.39 (1.53--3.74)^12^McAdams-DeMarco et al. (2012) \[[@CR20]\]5789225HR (95% CI)Diuretic use1.72 (1.32--2.25)1.48 (1.11--1.98)^13^Wilson et al. (2014) \[[@CR21]\]303343Mean number of days until incident\
gout (SD, range)Chlorthalidone (CTD) vs hydrochlorothiazide (HCTZ)CTD: 183.6\
(105.44, 21--362);\
HCTZ: 152.7 (107.60, 22--345)--Burke et al. (2016) \[[@CR23]\]2956\
3809120\
110HR (95% CI)Diuretic use in men\
Diuretic use in women1.58 (0.89--2.81)\
1.83 (1.12--2.98)-\
-*BMI* body mass index, *CI* confidence interval, *RR* relative risk, *OR* odds ratio, *HR* hazard ratio, *SD* standard deviation^a^Included in meta-analysis (*n* = 11)^b^Age-adjusted model^c^Age and sex-adjusted model^1--13^Maximal adjustment model outlined for each article in each risk factor (adjustment for other risk factor of interest highlighted in italics) as follows: Maximal adjustment models within obesity articles:^1^Age, total energy intake, *diuretic use*, history of *hypertension*, presence of chronic renal failure, meat intake, seafood intake, purine-rich vegetable intake, dairy food intake, alcohol intake, meat intake and fluid intake^2^Age, education level, alcohol consumption, *hypertension*, *diuretic use*, blood glucose level, cholesterol levels and menopausal status (women only)^3^Age, sex, alcohol intake, blood pressure, cholesterol and treatment for *hypertension* and hypercholesterolaemia^4^Age, menopausal status, race, diabetes mellitus, *hypertension*, *diuretic use*, alcohol intake, organ meat intake and estimated glomerular filtration rate Maximal adjustment model within hypertension articles:^5^Ethnicity and *BMI*^6^Age, total energy intake, *diuretic use*, *BMI*, presence of chronic renal failure, meat intake, seafood intake, purine-rich vegetable intake, dairy food intake, alcohol intake, meat intake and fluid intake^7^Age, education level, alcohol consumption, *diuretic use*, blood glucose level, cholesterol levels and menopausal status (women only)^8^Age, *obesity* (BMI ≥ 27 kg/m^2^), hyperlipidaemia, diabetes mellitus, alcohol drinking and cigarette smoking^9^Sex, race, *BMI*, alcohol intake and categorical estimated glomerular filtration rate^10^Age, sex, dialect, year of interview, educational level, *BMI***,** physical activity, smoking status, alcohol use and history of diabetes at follow-up I Maximal adjustment models within diuretic use articles:^11^Age, total energy intake, *BMI*, history of *hypertension*, presence of chronic renal failure, meat intake, seafood intake, purine-rich vegetable intake, dairy food intake, alcohol intake, meat intake and fluid intake^12^Age, education level, *BMI*, alcohol consumption, *hypertension*, blood glucose level, cholesterol levels and menopausal status (women only)^13^Sex, race, baseline *BMI*, categorical glomerular filtration rate and time-varying *blood pressure*

The covariates which each article included in its maximal adjustment model are described in detail in Table [2](#Tab2){ref-type="table"}; however, the majority of articles adjusted for age, gender, co-morbidities, alcohol intake and food/energy intake. Several adjustment models included specific covariates; however, each of the three risk factors of interest was typically adjusted for both of the other two risk factors. Therefore, of the four obesity articles, all adjusted for hypertension and three adjusted for diuretic use; of the six hypertension articles, five adjusted for BMI and two adjusted for diuretic use; and finally, all three of the articles examining diuretic use as a risk factor for gout adjusted for hypertension and BMI.

Quality appraisal of articles included in the meta-analysis {#Sec11}
-----------------------------------------------------------

Three of the 11 studies (27%) included a specific sample (male healthcare professionals (*n* = 1), medical students (*n* = 2)) \[[@CR11], [@CR12], [@CR14]\]. Six articles (55%) ascertained exposure using a secure record or structured interview, ranking as the highest quality approach \[[@CR11], [@CR13], [@CR15], [@CR17], [@CR22], [@CR23]\]. Eight articles (73%) specifically mentioned that they had excluded participants with prevalent gout at the beginning of the study \[[@CR14]--[@CR18], [@CR22], [@CR23], [@CR25]\]. No studies required the diagnosis of gout to be crystal proven, two studies (18%) defined gout through clinical diagnosis \[[@CR13], [@CR15]\] and, although the remaining nine studies had defined a new gout diagnosis through self-report, four of these additionally used the ACR criteria \[[@CR14]\] or a review of the medical records \[[@CR11], [@CR12], [@CR22]\] to support the definition. Three articles (27%) provided unadjusted risk estimates only \[[@CR11], [@CR13], [@CR23]\], with the remaining articles providing results with adjustment for at least two confounding factors. Eight articles (73%) provided a description of those lost to follow-up \[[@CR11], [@CR12], [@CR14]--[@CR17], [@CR22], [@CR23]\] (Appendix [3](#Sec20){ref-type="sec"}). Funnel plots for each meta-analysis did not demonstrate any discernible asymmetry (Appendix [4](#Sec21){ref-type="sec"}).

Obesity {#Sec12}
-------

For obesity, four articles met the inclusion criteria, all of which were suitable for pooling as all had defined obesity as BMI ≥ 30 kg/m^2^ and provided the RR for incident gout. All articles conducted multivariate analysis; two risk estimates were included from the article by Bhole et al. \[[@CR15]\] which reported RRs separately for men and women.

The pooled unadjusted/age-adjusted RR of incident gout in obese individuals compared with non-obese individuals was 2.84 (95% CI 2.15--3.76). The corresponding pooled multivariate-adjusted RR was 2.24 (1.76--2.86). There was no evidence of any statistically significant heterogeneity between the risk estimates as reflected by the low *I*^2^ values and non-significant *p* value (*I*^2^ = 21.4%, *p* = 0.278) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Forest plot showing pooled risk estimates for incident gout associated with body mass index ≥ 30 kg/m^2^. BMI body mass index, CI confidence interval

Hypertension {#Sec13}
------------

For hypertension, 10 articles met the inclusion criteria; of these, five provided RRs and four provided HRs which were suitable for pooling. For the RR meta-analysis, all five articles provided unadjusted/age-adjusted RRs, but only three articles provided multivariate-adjusted RRs. The pooled unadjusted/age-adjusted RR for incident gout in hypertensive individuals was almost three times higher than that in normotensive individuals (RR 2.98 (95% CI 2.63--3.37)). On pooling multivariate RRs, this risk was reduced, but remained significant (2.11 (1.64--2.72)). There was no evidence of any statistically significant heterogeneity between the risk estimates (*I*^2^ = 48.3%, *p* = 0.122) (Fig. [3](#Fig3){ref-type="fig"}). For the HR meta-analysis, three articles provided unadjusted/age-adjusted HRs \[[@CR18], [@CR23], [@CR25]\] and three provided multivariate-adjusted HRs \[[@CR18], [@CR22], [@CR25]\]. The pooled unadjusted/age-adjusted HR for incident gout in hypertensive individuals was almost two times higher than that in normotensive individuals (RR 1.93 (95% CI 1.52--2.46)). On pooling multivariate HRs, this risk was reduced, but remained significant (1.64 (1.34--2.01)). However, heterogeneity was reported as statistically significant (*I*^2^ = 78.6%, *p* = 0.001) (Fig. [4](#Fig4){ref-type="fig"}).Fig. 3Forest plot showing pooled risk estimates (relative risk) for incident gout associated with hypertension. CI confidence intervalFig. 4Forest plot showing pooled risk estimates (hazard ratios) for incident gout associated with hypertension. CI confidence interval

Diuretic use {#Sec14}
------------

Three of the six articles which met the inclusion criteria for diuretic use were suitable for inclusion in the meta-analysis. Only two studies provided multivariate-adjusted RRs suitable for pooling; however, these studies provided three relevant adjusted risk estimates. The pooled unadjusted/age-adjusted RR of incident gout in people taking diuretics compared to those not taking diuretics was 3.59 (95% CI 3.06--4.21). The corresponding pooled adjusted RR was 2.39 (1.57--3.65). Evidence for statistically significant heterogeneity was identified for the pooled multivariate-adjusted RRs (*I*^2^ = 79.1%, *p* = 0.008), but not for the unadjusted/age-adjusted RRs (*I*^2^ = 0.0%, *p* = 0.397) (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Forest plot showing pooled risk estimates for incident gout associated with diuretic use. CI confidence interval

Discussion {#Sec15}
==========

This systematic review and meta-analysis of cohort studies has shown that in primary care and general populations, obesity, hypertension and diuretic use are all independent risk factors for incident gout. Each of these more than doubled the risk of developing gout.

Although this is the first meta-analysis of hypertension as a risk factor for gout, our findings for the other risk factors of obesity and diuretic use are supported by previous reviews. Our findings concerning obesity are consistent with those of a recent systematic review and meta-analysis which found that increasing BMI was a risk factor for the development of gout \[[@CR26]\]. However, in contrast to our research, this meta-analysis included case--control studies as well as cohort studies, and included some studies of populations with hyperuricaemia, who are at greater risk of gout than the general population, perhaps explaining higher relative risks than those seen in our study. Hueskes et al. \[[@CR8]\] published a systematic review examining the risk of gout associated with diuretics. They concluded that there was a trend that patients using either loop or thiazide diuretics were at an increased risk of gout; however, they reported that the magnitude and independence of this association in different studies was inconsistent and that evidence to support stopping diuretics in those with gout was lacking \[[@CR8]\]. An important consideration is that their outcome was specifically defined as 'acute gouty arthritis' or 'chronic tophaceous gout', which is in contrast to the more inclusive outcome used in this study which was incident gout. This previous study did not attempt to pool risk estimates from different studies and was therefore unable to quantify the risk incurred by diuretic use. This systematic review also included randomised controlled trials, cohort studies and case--control studies, whereas our review included only cohort studies.

We have shown that obesity, hypertension and diuretic use are all important risk factors for incident gout. The prevalence of obesity is rising within the UK as well as globally and it has been linked to co-morbidities and mortality; as a result, the obesity epidemic has become a major public health concern. Previous research has demonstrated the benefits of weight reduction interventions in preventing gout \[[@CR27]\] and our study has added further evidence to the need to tackle obesity due to its strong association with gout. Hypertension is primarily managed in primary care; careful selection of therapeutic agents can help to reduce the risk of future gout. This study also suggests that diuretics should be avoided in those at risk of developing gout, where possible, and alternatives considered.

Our study had a number of strengths including the comprehensive search strategy and literature review process, with no restrictions on language. By considering only primary care and population-based cohort studies for inclusion, we ensured that the results would be generalisable to most patients with gout, who are managed exclusively in primary care. We only included cohort studies in our review, reducing the effect of recall bias frequently encountered in case--control studies and allowing certainty of any temporal relationships between exposure and outcome \[[@CR28]\]. Finally, as the risk estimates included in the meta-analyses were adjusted for the other risk factors of interest (i.e. obesity estimates were adjusted for hypertension, hypertension estimates were adjusted for diuretic use, etc.), we are confident these risk estimates are independent. As a result, it appears that hypertension is a risk factor for gout independent of diuretic use, but none of the included studies adjusted for other anti-hypertensive drugs which can cause hyperuricaemia. Therefore, we were unable to investigate whether the effect of hypertension was also independent of these.

Limitations in our work include that some studies had used specific samples (e.g. health professionals, university students), meaning their sampling frames with lower social deprivation are likely to underestimate the risk of incident gout. Other limitations include, firstly, that one-quarter of the articles did not specifically indicate that they had excluded individuals with a previous diagnosis of gout and, secondly, that variation may exist between pooled multivariate relative risks due to adjustments for different factors within different studies. However, regarding this latter point, several factors were the same (e.g. age, gender) and the majority of articles adjusted for the most important factors (in the case of this review, BMI, hypertension and/or diuretic use). In relation to this, although we are confident on the role of risk for each of these three variables, we are unable to address risk through different interactions of these, which would be clinically useful. Finally, diagnosis of gout was predominantly determined through self-report as no study required gout to be defined using the gold standard of crystal visualisation in the synovial fluid. This raises the possibility of misclassification; however, this approach is not unusual in large population/primary care-based epidemiological studies.

Conclusion {#Sec16}
==========

Obesity, hypertension and diuretic use are all risk factors for incident gout, independent of one another and each more than doubling the risk of developing gout compared with those without these conditions. Such patients should be recognised by clinicians as being at greater risk of developing gout and provided with appropriate management and treatment options. Future research into interactions between these individual risk factors would expand our understanding of the epidemiology and pathophysiology of gout. As diuretic use in hypertensive patients is likely and a large proportion of such patients will be overweight, future research should consist of prospective studies which consider the interaction between co-morbidities and examine how certain clusters of co-morbidities influence the risk of developing gout, building on the work of Richette et al. \[[@CR29]\].

Appendices {#Sec17}
==========

Appendix 1 {#Sec18}
----------

Table 3Search Strategy**Gout search terms**exp Gout/gout\*.ti,ab.podagra.ti,ab.toph\*.ti,ab.MeSH descriptor: \[Gout\] explode all trees *(Cochrane search only)***Obesity search terms**exp Obesity/obes\*.ti,ab.Body Mass Index/BMI.ti,ab.MeSH descriptor: \[Obesity\] explode all trees *(Cochrane search only)*MeSH descriptor: \[Body Mass Index\] this term only *(Cochrane search only)***Hypertension search terms**exp Hypertension/hypertens\*.ti,ab.(blood adj3 pressure).ti,ab.MeSH descriptor: \[Hypertension\] this term only (*Cochrane search only)***Diuretics search terms**exp Diuretics/(loop adj3 diuretic\*).ti,ab.(high-ceiling adj3 diuretic\*).ti,ab.MeSH descriptor: \[Diuretics\] explode all trees *(Cochrane search only)*
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Table 4:Articles reviewed in full, but subsequently excluded (n=35)AuthorYearArticle titleReason for exclusionOgryzlo1960The renal factor in the etiology of primary goutNot cohortMertz & Schindera1968Secondary gout six years after acute renal failureNot cohortDe Muckadall & Gyntelberg1976Occurrence of gout in Copenhagen males aged 40-59Gout not an outcomeSeidell et al1985Fat distribution of overweight persons in relation to morbidity and subjective healthGout not an outcomeTsitlanadze et al1987Incidence and various risk factors for gout in the Georgian SSRNot cohortVan Noord et al1990The relationship between fat distribution and some chronic diseases in 11,825 women participating in the DOM-projectGout not an outcomeHoiberg & McNally1991Profiling overweight patients in the US Navy: Health conditions and costsBased on RCTScott & Higgens1992Diuretic induced gout: A multifactorial conditionNot cohortYoussef et al1995Does renal impairment protect from gout?Not cohortGurwitz et al1997Thiazide diuretics and the initiation of anti-gout therapyNot cohortLin et al2000Community based epidemiological study on hyperuricemia and gout in Kin-Hu, KinmenNot general populationLin et al2000The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective studyNot cohortTakahashi et al2000Increased visceral fat accumulation in patients with primary goutNot cohortLin et al2006Association of obesity and chronic disease in TaiwanNot cohortMiao et al2008Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern ChinaNot cohortZhu et al2010The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention TrialNot cohortBarskova et al2011Main factors of gender dimorphism of gout (estrogens and diuretics vs alcohol and genetics)Not cohortChang2011Dietary intake and the risk of hyperuricemia, gout and chronic kidney disease in elderly Taiwanese menNot cohortKawashima et al2011Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort studyGout not an outcomePrimatesta et al2011Gout treatment and comorbidities: A retrospective cohort study in a large US managed care populationGout not an outcomeLin et al2012Prevalence of hyperuricemia and its association with antihypertensive treatment in hypertensive patients in TaiwanNot cohortChen et al2013Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: A prospective studyNot cohortKrishnan2013Chronic kidney disease and the risk of incident gout among middle-aged men: a seven-year prospective observational studyNot cohortLin et al2013The association of anthopometry indices with gout in Taiwanese menNot cohortMcAdams-DeMarco et al2013A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC studyNot cohortOzturk et al2013Demographic and clinical features of gout patients in Turkey: a multicenter studyNot general populationWang et al2013Risk factors for gout developed from hyperuricemia in China: a five-year prospective cohort studyNot general populationLu et al2014Contemporary epidemiology of gout and hyperuricemia in community elderly in BeijingGout not an outcomePan et al2015Bidirectional association between hypertension and gout: The Singapore chinese health studyNot cohortWang et al2015Chronic kidney disease as a risk factor for incident gout among men and women: retrospective cohort study using data from the Framingham Heart StudyNot general populationAbeles et al2015Hyperuricemia, gout, and cardiovascular disease: an updateNot cohortBao et al2015Lack of gene-diuretic interactions on the risk of incident gout: the Nurses\' Health Study and Health Professionals Follow-up StudyNot general populationJing et al2015Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) studyNot general populationDalbeth et al2015Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and goutNot cohortDrivelegka et al2016Comorbidity pattern at the time of gout diagnosis: A population- and register-based case-control study from Western SwedenNot cohort
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Table 5:Quality appraisal scores of articles included in meta-analysis using the Newcastle-Ottawa Scale (NOS)ArticleSelectionComparabilityOutcome12341123Is exposed cohort representative?How was non-exposed cohort selected?How was exposed cohort selected?Clear, outcome wasn't present?Are cohorts compatible?How was outcome assessed?Was follow-up long enough?Adequate cohort sample followed-up?Roubenoff et al. 1991CA\*A\*BA\*, B\*B\*A\*B\*Hochberg et al. 1995CBDBA\*, B\*B\*A\*B\*Grodzicki et al. 1997B\*A\*A\*B-B\*BDChoi et al. 2005CA\*CA\*A\*, B\*B\*A\*B\*Bhole et al. 2010A\*A\*A\*A\*A\*, B\*B\*A\*B\*McAdams-DeMarco et al. 2011A\*A\*CA\*A\*, B\*CA\*B\*Maynard et al. 2012B\*A\*A\*A\*A\*, B\*CA\*B\*Chen et al. 2012A\*A\*A\*A\*A\*, B\*B\*A\*B\*McAdams-DeMarco et al. 2012B\*A\*A\*A\*A\*, B\*CA\*B\*Pan et al. 2015A\*A\*B\*A\*A\*, B\*CA\*DBurke et al. 2016B\*A\*A\*A\*A\*, B\*CA\*DA indicates the highest methodological quality whereas D indicates the worst quality; An asterisk (\*) denotes that the article has scored highest for that particular criterion. A comma (,) separating two scores denotes that an article i) matched exposed and non-exposed and ii) adjusted for potential confounding factors
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Fig. 6**a** Funnel plot of adjusted relative risk estimates for obesity. **b** Funnel plot of adjusted relative risk estimates for hypertension. **c** Funnel plot of adjusted hazard ratio estimates for hypertension. **d** Funnel plot of adjusted relative risk estimates for diuretic use

ARIC

:   Atherosclerosis Risk In Communities

BMI

:   Body mass index

CI

:   Confidence interval

HR

:   Hazard ratio

MeSH

:   Medical subject headings

NOS

:   Newcastle--Ottawa Scale

OR

:   Odds ratio

RR

:   Risk ratio

ULT

:   Urate lowering therapies
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